Q-omics provides the consensus-scored TMEM182 profile across patient tissues and cancer cell-line models. TMEM182 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, TMEM182 is differentially expressed in 15, with the highest sampling consensus in LUAD. Additionally, TMEM182 RNA expression shows 20,160 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, LUAD, and UVM as cancer lineages where TMEM182 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM182 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM182 survival associations across molecular data types. TMEM182 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM182 RNA expression–survival associations across cancer types. High TMEM182 expression shows unfavorable associations in KICH, KIRP, UCEC, UVM and LGG, but favorable associations in UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for TMEM182 RNA expression.
This table summarizes TMEM182 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM182. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM182 shows lower tumor expression in KICH and higher tumor expression in LUAD, KIRP, COAD, STAD and LUSC. The LUAD box plot shows higher TMEM182 RNA expression in tumor versus normal tissue (log2 FC = +1.555, t-test p < 0.001).
This table shows molecular features associated with TMEM182 in patient tissues and cancer cell lines. In patient samples, TMEM182 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM182 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
